Ultragenyx cut to Market Perform on lack of catalysts at Raymond James

Raymond James downgraded Ultragenyx to Market Perform from Outperform. Analyst Laura Chico said Ultragenyx lacks near-term catalysts which makes it more vulnerable in a “risk off” environment. Chico remains encouraged by the Crysvita launch, but said the company is only proportion of the economics.
https://thefly.com/landingPageNews.php?id=2842469